GSK plc 13F holders
Of the 44 funds followed here, 8 reported a position in GSK plc in a 13F for the quarter ended 30 June 2026. The largest: FMR LLC, 65.0 million shares worth $3.41 billion, 0.1% of its reported book. New this quarter: Point72 Asset Management. Sold out: Renaissance Technologies, Alyeska.
| Fund | Shares | Value | Of its book | Change on the quarter | Status | Quarter ended | Filing |
|---|---|---|---|---|---|---|---|
| FMR LLC | 64,961,641 | $3.41 billion | 0.1% | -2,700,005 | trimmed | 30 June 2026 | 13F |
| Dodge & Cox | 48,197,514 | $2.53 billion | 1.3% | -10,465,460 | trimmed | 30 June 2026 | 13F |
| Point72 Asset Management | 2,661,281 | $139.5 million | 0.2% | +2,661,281 | new | 30 June 2026 | 13F |
| Citadel Advisors | 870,873 | $45.7 million | 0.0% | -403,427 | trimmed | 30 June 2026 | 13F |
| Bridgewater Associates | 504,171 | $26.4 million | 0.1% | -194,495 | trimmed | 30 June 2026 | 13F |
| Millennium Management | 398,600 | $20.9 million | 0.0% | -275,167 | trimmed | 30 June 2026 | 13F |
| Norges Bank | 200,000 | $10.5 million | 0.0% | held | 30 June 2026 | 13F | |
| Two Sigma Investments | 70,993 | $3.7 million | 0.0% | +66,993 | added | 30 June 2026 | 13F |
| Renaissance Technologies | 0 | $0 | 0.0% | -311,292 | exited | 30 June 2026 | 13F |
| Alyeska | 0 | $0 | 0.0% | -1,210,746 | exited | 30 June 2026 | 13F |
Value is what the fund reported. Change is shares against the fund's previous 13F; a fund with one filing read shows no change. 13Fs cover long US positions of managers above $100 million and are filed up to 45 days after the quarter.
Schedule 13D and 13G filed on the name, last twelve months
| Filed | Schedule | Who | Holding | Of the class | Event date | Rule or purpose | Filing |
|---|---|---|---|---|---|---|---|
| 13 August 2026 | 13G/A | Dodge & Cox and 1 other | 173.3 million | 4.3% | 30 June 2026 | passive, institutional (13d-1(b)) | EDGAR |
| 6 May 2026 | 13G | Fmr Llc and 3 others | 234.9 million | 5.8% | 31 March 2026 | passive, institutional (13d-1(b)) | EDGAR |
A Schedule 13D is filed by anyone who crosses 5% of a class with intent to influence; a 13G by a passive holder. Amendments (/A) report a change, including an exit to zero. Holding and percentage are as the filer stated them on the cover page; the purpose is the filer's own words, cut short.
Fails to deliver
| Settlement date | Shares failed | Price | File |
|---|---|---|---|
| 28 August 2026 | 4,454 | $50.27 | SEC |
| 27 August 2026 | 79 | $51.43 | SEC |
| 14 August 2026 | 39,991 | $50.45 | SEC |
| 13 August 2026 | 75 | $50.30 | SEC |
| 12 August 2026 | 90,888 | $50.90 | SEC |
| 7 August 2026 | 279 | $52.17 | SEC |
| 6 August 2026 | 38,334 | $51.46 | SEC |
| 5 August 2026 | 28,269 | $51.53 | SEC |
| 4 August 2026 | 12,472 | $51.51 | SEC |
| 27 July 2026 | 3 | $51.35 | SEC |
| 21 July 2026 | 120 | $50.04 | SEC |
Shares that failed to deliver at settlement, per day, from the SEC's half-month files, which arrive about two weeks after the period. Largest in the window: 90,888 on 12 August 2026. A fail is an operational fact about settlement, not a position.
Source
Each fund's 13F-HR on EDGAR, linked per row; positions matched to GSK by CUSIP from the SEC's own fails-to-deliver files; Schedule 13D and 13G from the company's own filing index, each read to confirm the company is the issuer named.
The same record on your computer
GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.